IRADIMED Corporation Announces Second Quarter 2026 Results: Dividend Declared, Guidance Reaffirmed
Key Highlights from the Q2 2026 Report
- Q2 Revenue: \$20.5 million, up 0.5% year-over-year
- GAAP Net Income: \$5.2 million for the quarter
- GAAP Diluted EPS: \$0.41 per share
- Non-GAAP Net Income: \$5.9 million
- Non-GAAP Diluted EPS: \$0.46 per share
- Cash Dividend Declared: \$0.20 per share, payable August 28, 2026 to shareholders of record as of August 14, 2026
- Free Cash Flow: \$5.5 million for Q2
- Cash and Cash Equivalents: \$57.8 million as of June 30, 2026
- Guidance: Full-year 2026 revenue and earnings guidance reaffirmed
Detailed Financial Performance
IRADIMED Corporation (NASDAQ: IRMD), a leading provider of MRI-compatible medical devices, reported second quarter 2026 revenue of \$20.5 million, representing a slight but positive increase of 0.5% from the same quarter in 2025. The company continues to demonstrate strong profitability with a GAAP net income of \$5.2 million and diluted earnings per share (EPS) of \$0.41 for the quarter.
On a non-GAAP basis, which excludes stock-based compensation, net income was \$5.9 million, translating to a non-GAAP diluted EPS of \$0.46. Free cash flow generation remained robust with \$5.5 million for the quarter, and IRADIMED ended the period with \$57.8 million in cash and cash equivalents, highlighting a strong liquidity position.
Dividend Announcement
The Board of Directors has declared a regular quarterly cash dividend of \$0.20 per share of outstanding common stock. The dividend is scheduled for payment on August 28, 2026, to shareholders of record as of the close of business on August 14, 2026. This ongoing commitment to dividends underlines management’s confidence in the company’s financial stability and future prospects.
Shareholder-Relevant and Potentially Price-Sensitive Updates
- Steady Growth: While revenue growth was modest, IRADIMED maintained profitability and strong free cash flow, supporting ongoing shareholder returns through dividends.
- Guidance Reaffirmed: The company reaffirmed its full-year 2026 revenue and earnings guidance, signaling management’s expectation of continued stable performance through the remainder of the year.
- Product Pipeline: The company referenced ongoing commercialization and anticipated revenue ramping of its next-generation 3870 MRI-compatible IV infusion pump, which may represent a future growth catalyst. Shareholders should monitor progress on regulatory clearances (e.g., 510(k)) and market adoption.
- Regulatory and Operational Risks: The press release includes standard forward-looking statements and outlines risks such as potential regulatory delays (especially concerning FDA clearances), supply chain issues, and macroeconomic factors. Any materialization of these risks could impact future performance and share value.
Condensed Balance Sheet Snapshot (as of June 30, 2026)
- Total Assets: \$108.8 million
- Total Stockholders’ Equity: \$94.6 million
- Accounts Payable: \$14.2 million
Conference Call Information
IRADIMED will host a conference call to discuss these results at 11:00 a.m. Eastern Time on July 31, 2026. Interested parties can register here. The call will also be webcast in real-time on the company’s website.
For further information, please visit the company’s website at www.iradimed.com.
Outlook and Potential Share Price Movers
- Dividend Continuity: The ongoing dividend policy and cash generation may appeal to income-oriented investors and support share price stability.
- Product Commercialization: Any material news on regulatory clearance or commercialization of the next-generation MRI IV pump may act as a significant share price catalyst.
- Regulatory Developments: As with all medical device companies, FDA or other regulatory actions—positive or negative—could materially affect performance and share value.
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Forward-looking statements are subject to risks and uncertainties, and actual results may differ materially. Investors should conduct their own due diligence and consult with financial advisors before making investment decisions. IRADIMED’s filings with the SEC, including risk factors, should be reviewed for a comprehensive understanding of risks and opportunities.
